DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: BRIUMVI (ublituximab)
       *****************************************************
       #Post#: 4920--------------------------------------------------
       Briumvi sales doing well
   DIR By: agate
       Date: September 7, 2025, 1:17 am
       ---------------------------------------------------------
       This board doesn't usually feature financial reports but it may
       be of interest that:
       --- Quote ---
       >
       > [/size][TG Therapeutics'] primary revenue driver, BRIUMVI, is
       rapidly establishing itself as a commercial success story. TG
       Therapeutics reported total second-quarter 2025 revenue of
       $141.1 million, with U.S. sales of BRIUMVI contributing $138.8
       million to this figure. This represents a substantial 91 percent
       year-over-year increase, highlighting the therapy's accelerating
       market adoption for multiple sclerosis treatment.
       > [/size]
       > [/size]In response to this powerful sales trajectory,
       management has significantly raised its full-year 2025 guidance.
       Instead of previous projections, TG Therapeutics now anticipates
       approximately $570 to $575 million in U.S. BRIUMVI revenue
       alone—a strong indicator of continued robust demand.
       > [/size]
       --- End Quote ---
       ktiencheck.de/news/Artikel-TG_Therapeutics_Stock_Riding_a_Wave_of_Commercial_Success-18985749
  HTML https://msspeaks.createaforum.com/ktiencheck.de/news/Artikel-TG_Therapeutics_Stock_Riding_a_Wave_of_Commercial_Success-18985749
       *****************************************************
       Page 1 of 1